Orange Juice Diet Reduces Colon Cancer Incidence in Animal Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

WASHINGTON-Rats with chemically induced colon cancer that were fed orange juice for 4 weeks had a significantly lower incidence of colon cancer tumors than those receiving water, in a study at Michigan State University, East Lansing. Maurice R. Bennink, PhD, professor of food science and human nutrition, presented the results at the American Institute for Cancer Research 9th Annual Research Conference.

WASHINGTON—Rats with chemically induced colon cancer that were fed orange juice for 4 weeks had a significantly lower incidence of colon cancer tumors than those receiving water, in a study at Michigan State University, East Lansing. Maurice R. Bennink, PhD, professor of food science and human nutrition, presented the results at the American Institute for Cancer Research 9th Annual Research Conference.

Previous studies have shown that certain flavanones, limonoids, and cumarins present in citrus fruits can inhibit chemically induced cancer in animals. But, Dr. Bennink said, “it would be inappropriate to extrapolate from these results with purified citrus phytochemicals that consuming a citrus product such as orange juice will inhibit cancer.” The current study was designed to determine if single-strength, pasteurized orange juice would inhibit azoxymethane-induced colon cancer in male Fisher 344 rats.

The researchers replaced drinking water with orange juice in the diets of the experimental group of 30 rats for 28 weeks. Growth and weight gain were similar in both groups during the study, but feeding orange juice to the rats reduced tumor incidence by 22%.

Tropicana Products, Inc. provided Tropicana Pure Premium orange juice and financial support for the study.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content